This is consistent with the latest recommendations from the Chinese chronic hepatitis B guideline (2022 version), which state that antiviral therapy is recommended for patients with detectable HBV DNA and persistently elevated ALT levels (> ULN) after excluding other causes [5]. The gene discussed is GPT; the disease is chronic hepatitis B virus infection.